Processa Pharmaceuticals, Inc. Deferred Income Tax Liabilities, Net
Processa Pharmaceuticals, Inc. (PCSA) had Deferred Income Tax Liabilities, Net of $181.75 thousand as of 2021-09-30, per its 10-Q filed 2021-11-12.
Discontinued › Balance Sheet › Liabilities › Liabilities, Noncurrent › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:DeferredIncomeTaxLiabilitiesNet · last filed 2022-03-30
- 2021-09-30: Deferred Income Tax Liabilities, Net $181.75K.
- 2021-06-30: Deferred Income Tax Liabilities, Net $304.19K.
- 2021-03-31: Deferred Income Tax Liabilities, Net $441.36K.
- 2020-12-31: Deferred Income Tax Liabilities, Net $530.61K.
| Period end | Deferred Income Tax Liabilities, Net |
|---|---|
| 2021-09-30 | $181.75K 10-Q · filed 2021-11-12 |
| 2021-06-30 | $304.19K 10-Q · filed 2021-08-12 |
| 2021-03-31 | $441.36K 10-Q · filed 2021-05-13 |
| 2020-12-31 | $530.61K 10-K · filed 2022-03-30 |
| 2020-09-30 | $1.25M 10-Q · filed 2020-11-12 |
| 2020-06-30 | $1.32M 10-Q · filed 2020-08-05 |
| 2020-03-31 | $1.40M 10-Q · filed 2020-05-15 |
| 2019-12-31 | $1.53M 10-K · filed 2021-03-25 |
| 2018-12-31 | $2.13M 10-K · filed 2020-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |